CM-ONE Human Cardiomyocytes: the CD15 revolution

Millions have been spent over the decades on attempts to identify a receptor specific to adult cardiac cells, but with little success. Univercell-Biosolutions’ founding scientists took an original approach, by looking for membrane antigens expressed during the initial steps of cardiogenesis. In 2007 they succeeded in identifying the membrane antigen CD15 as a unique marker suitable for selecting highly pure populations of pre-cardiomyocytes (Mesopure®), and thus for producing enriched mature human cardiomyocytes. CD15 is a membrane antigen induced by the cardiogenic TGFbeta  superfamily members.

Key benefits

  1. Specificity required to yield >99% pure human pre-cardiomyocytes.
  2. Physiologically relevant method respecting cell integrity and capability to predict human effects.
  3. Pre-cardiomyocytes that are directed to differentiate into functional human cardiomyocytes suitable for industrial applications, and particularly for electrophysiological studies.
CD 15+ cells after selection
CM-ONE® human cardiomyocytes

CM-ONE® cardiomyocytes: product specifications
Cell Type Cardiomyocytes
Organism Human
Origin Human hiPS cell lines
Early cardiac gene expression Isl1+, Mef2c+, Nkx2.5+,Tbx5+
Late cardiac Biomarkers AlphaMHC+, MLC2v+
Quantity 24- or 96-well plates
Shipping Fresh
Storage 37°C
Viability Up to 2 weeks

Key benefits: maximized predictability

  • Human cells
  • Cardiomyocytes derived from a human iPS cell line
  • Ready-to-use
  • Highly homogeneous and pure (Mesopure®)
  • Physiological sorting method


  • Voltage clamp
  • Manual patch clamp
  • Microelectrode array
  • Apoptosis (viability)
  • Gene expression studies
  • Mitochondrial dysfunction
  • Oxidative stress
  • Transfection
  • Teratogenesis

References: publications

Embryonic Stem Cells: From Bench to Bedside.
Clin Pharmacol Ther. 2007 82(3):337-9 review
Puceat M
, Ballis A.

Differentiation in vivo of Cardiac Committed Human Embryonic Stem Cells in Post-myocardial Infarcted Rats.
Stem Cells. 2007 (9):2200-5
Tomescot A, Leschik J, Bellamy V, Dubois G, Messas E, Bruneval P, Desnos M, Hagege AA, Amit M, Itskovitz J, Menasche P, Puceat M.

Human embryonic stem cell: Is it a realistic cell source for regenerative therapy of heart failure?
Pathol Biol (Paris). 2008 Mar;56(2):47-49. Review
Pucéat M.

Pharmacological approaches to regenerative strategies for the treatment of cardiovascular diseases.
Curr Opin Pharmacol. 2008 Apr;8(2):189-92. Review
Pucéat, M

Protocols for cardiac differentiation of embryonic stem cells.
Methods. 2008 Jun;45(2):168-71.
Pucéat M.

Cardiac commitment of Primate Embryonic Stem cells Nature Protocols 2008;3(9):1381-7.
Leschik, J, Stefanovic S, Brinon, B (co-1st authors), Pucéat M

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy.
ALTEX. 2008;25(3):163-90.
Leist M, Bremer S, Brundin P, Hescheler J, Kirkeby A, Krause KH, Poerzgen P, Puceat M, Schmidt M, Schrattenholz A, Zak NB, Hentze H.

Human embryonic stem cells and cardiac cell fate.
J Cell Physiol. 2009 Mar;218(3):455-9. Review
Nury D, Neri T, Pucéat M.

Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate
Sonia Stefanovic, Nesrine Abboud, Stéphanie Désilets, David Nury, Chad Cowan, Michel Pucéat. J. Cell. Biol. 2009 186:665-73

A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in post-myocardial infarcted non-human primates Blin G*, Nury*, D, Stefanovic*, S, Neri, T, Guillevic, O, Brinon, B, Bellamy, V, Rücker-Martin, C, Barbry, P, Bel,  A, Bruneval, P, Cowan, C, Pouly, J, Mitalipov, S, Gouadon, E, Binder,P,  Hagège, A, Desnos, M, Renaud, JF, Menasché, M, Pucéat,M. *co-1st authors.. J Clin. Invest. 2010 120(4):1125-39

Human embryonic and induced pluripotent stem cells in basic and clinical research in cardiology. Current Stem Cell Research. Review 2010 5(3):215-26. BG, NT and SS listed by alphabetical order equally contributed to this work.
Blin G, Neri T, Stefanovic S, Pucéat M.